(Q38020180)

27 August 2017

title

Chromophobe renal cell carcinoma: a review of an uncommon entity (English)

1 reference

chromophobe renal cell carcinoma

27 August 2017

main subject

1 reference

1 reference

Francisco Vera-Badillo

series ordinal

1

object named as

Francisco Emilio Vera-Badillo

1 reference

27 August 2017

Esther Conde

2

1 reference

27 August 2017

Ignacio Duran

series ordinal

3

1 reference

27 August 2017

publication date

21 June 2012

1 reference

International Journal of Urology

27 August 2017

published in

1 reference

27 August 2017

volume

19

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

894-900

1 reference

27 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Treatment of metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Novel approaches in the therapy of metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

The Heidelberg classification of renal cell tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Safety reporting in randomized trials of mental health interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Chromophobe cell renal carcinoma and its variants--a report on 32 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Parvalbumin Is Constantly Expressed in Chromophobe Renal Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Tumour necrosis in chromophobe renal cell carcinoma: clinical data to distinguish aggressive variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Molecular pathology of chromophobe renal cell carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Targeted therapies for non-clear renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Overexpression of KIT in chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Chromophobe Cell Renal Carcinoma: Clinicopathological Features of 50 Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Pathobiology and prognosis of chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Molecular classification of renal tumors by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Renal Tumors in the Birt-Hogg-Dubé Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Expression of vascular endothelial growth factor protein in human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2012.03079.X

10.1111/J.1442-2042.2012.03079.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference